Sarah Sevilla, PA
Medical · Las Vegas, NVNPI 1366132995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,703, 2.8 times the $619 reported in 2023.
Across 133 payments — averaging $28.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$801
- Dendreon Pharmaceuticals LLC$560
- Astellas Pharma US Inc$387
- Johnson & Johnson$336
- Pfizer$308
- Urogen Pharma, Inc.$169
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,62697%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 39 | $801 |
| Dendreon Pharmaceuticals LLC | 13 | $560 |
| Astellas Pharma US Inc | 4 | $387 |
| Johnson & Johnson | 12 | $336 |
| Pfizer | 11 | $308 |
| Urogen Pharma, Inc. | 7 | $169 |
| Abbott | 1 | $141 |
| Telix Pharmaceuticals | 5 | $133 |
| Teleflex LLC | 3 | $83 |
| Antares Pharma, Inc. | 5 | $78 |
| Merck | 3 | $75 |
| Bayer | 3 | $65 |
| Progenics Pharmaceuticals, Inc. | 2 | $64 |
| AbbVie | 3 | $56 |
| Endo USA, Inc. | 2 | $45 |
| Halozyme Inc | 2 | $36 |
| 180 Medical, Inc. | 2 | $35 |
| Blue Earth Diagnostics | 2 | $34 |
| Boston Scientific | 1 | $31 |
| Novartis | 1 | $31 |
| Olympus America Inc. | 2 | $30 |
| Immunitybio, Inc. | 1 | $28 |
| Tempus AI, Inc | 1 | $27 |
| Coloplast | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $25 |
| Bioprotect Medical, Inc. | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $23 |
| Innovation Technologies Inc | 1 | $20 |
| Amgen | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$239
- XTANDI$229
- CARDIOMEMS$141
- PADCEV$138
How this compares
$3,726 in reported general payments places this provider in the 75th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 63 | $53,269 |
| GemtesaVibegron | 33 | $34,839 |
| Estradiol | 31 | $1,556 |
| Methenamine Hippurate | 18 | $1,383 |
| Tamsulosin Hcl | 135 | $1,236 |
| Testosterone Cypionate | 18 | $801 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 24 | $515 |
| Finasteride | 30 | $435 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $376 |
| Oxybutynin Chloride | 31 | $184 |
| Cephalexin | 16 | $172 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $158 |
| Sildenafil Citrate | 12 | $46 |
| Levofloxacin | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $387 | $53,26963 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $801 | $34,83933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.